Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis

被引:25
作者
Takahashi, Toru
Wada, Ikuo
Ohtsuka, Yoshinori
Munakata, Mitsuru
Homma, Yukihiko
Kuroki, Yoshio
机构
[1] Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 060, Japan
[2] Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima, Japan
[3] Fukushima Med Univ, Sch Med, Dept Pulm Med, Fukushima, Japan
[4] Hokkaido Univ, Med Adm Ctr, Sapporo, Hokkaido 060, Japan
关键词
alanyl-tRNA synthetase; autoantibody; autoimmunity; lung; molecular biology;
D O I
10.1111/j.1440-1843.2007.01140.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and objectives: The pathogenesis of IPF is unknown and it is hypothesized that immunological responses are involved. The purpose of this study was to detect autoantibodies in IPF patients and to identify the relevant antigens. Methods: Sera from 37 healthy subjects and 22 IPF patients who had no clinical symptoms of collagen vascular disease were examined for immunostaining of A549 human type II cells and human lung tissue. Immunoprecipitation and proteome analysis were performed to identify the antigen. Results: Fifty per cent of the patient sera and none of the control sera exhibited positive staining. Sera from 10 of the 22 IPF patients showed positive immunohistochemistry and immunoprecipitated a 110-kDa protein from the A549 cell lysate. Sera from only two of 41 patients with collagen vascular disease showed positive immunoreactivity. Proteome analysis using tandem mass spectrometry revealed that the protein was alanyl-tRNA synthetase. Transfection of cDNA of this enzyme into CHO-K1 cells conferred positive staining on these cells with the patients' IgG. The 135-kDa fusion protein consisting of 108-kDa enzyme protein and 27-kDa YFP from the cell lysate of the transfected cells was immunoprecipitated by the patient IgG. In addition, sera from IPF patients significantly inhibited the enzyme activity of alanyl-tRNA synthetase. Conclusion: A significant number of IPF patients possess circulating autoantibodies against alanyl-tRNA synthetase, suggesting the involvement of an autoimmune background in the pathogenesis of IPF.
引用
收藏
页码:642 / 653
页数:12
相关论文
共 55 条
[1]  
BALDWIN ED, 1948, MEDICINE, V27, P243
[2]   Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis [J].
Baumgartner, KB ;
Samet, JM ;
Stidley, CA ;
Colby, TV ;
Waldron, JA ;
Coultas, DB ;
Davis, GS ;
Garcia, JGN ;
Hunninghake, GW ;
Kallay, MC ;
King, TE ;
Krowka, MJ ;
Rennard, SI ;
Ryu, JH ;
Sherman, CB ;
Smith, LJ ;
Toews, G ;
Winterbauer, RH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (01) :242-248
[3]   DETECTION OF ANTIBODIES IN SERUM OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AGAINST ISOLATED RAT ALVEOLAR TYPE-II CELLS [J].
BAUMGARTNER, U ;
SCHOLMERICH, J ;
BECHER, S ;
COSTABEL, U .
RESPIRATION, 1987, 52 (02) :122-128
[4]   ANTI-JO-1 ANTIBODY - A MARKER FOR MYOSITIS WITH INTERSTITIAL LUNG-DISEASE [J].
BERNSTEIN, RM ;
MORGAN, SH ;
CHAPMAN, J ;
BUNN, CC ;
MATHEWS, MB ;
TURNERWARWICK, M ;
HUGHES, GRV .
BRITISH MEDICAL JOURNAL, 1984, 289 (6438) :151-152
[5]   AUTOANTIBODIES AGAINST ALANYL-TRANSFER RNA-SYNTHETASE AND TRANSFER RNAALA COEXIST AND ARE ASSOCIATED WITH MYOSITIS [J].
BUNN, CC ;
BERNSTEIN, RM ;
MATHEWS, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (05) :1281-1291
[6]  
BURROWS B, 1961, AM REV RESPIR DIS, V84, P789
[7]   IDIOPATHIC PULMONARY FIBROSIS [J].
CAMPBELL, EJ ;
HARRIS, B ;
AVIOLI, LV .
ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (06) :771-774
[8]   INCREASED EXPRESSION OF THE INTERLEUKIN-8 GENE BY ALVEOLAR MACROPHAGES IN IDIOPATHIC PULMONARY FIBROSIS - A POTENTIAL MECHANISM FOR THE RECRUITMENT AND ACTIVATION OF NEUTROPHILS IN LUNG FIBROSIS [J].
CARRE, PC ;
MORTENSON, RL ;
KING, TE ;
NOBLE, PW ;
SABLE, CL ;
RICHES, DWH .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (06) :1802-1810
[9]  
CHAPMAN JR, 1984, AM REV RESPIR DIS, V130, P439
[10]   THE EPIDEMIOLOGY OF INTERSTITIAL LUNG-DISEASES [J].
COULTAS, DB ;
ZUMWALT, RE ;
BLACK, WC ;
SOBONYA, RE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (04) :967-972